Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Pancreatic Cancer
Drug:
temozolomide
(
DNA synthesis inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
05/23/2022
Excerpt:
Pancreatic Neuroendocrine Tumors (Well-Differentiated Grade 1/2)...Preferred Regimens...Temozolomide + capecitabine...
Secondary therapy:
capecitabine
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.